Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 6/20 | 0.55 |
| ▸ | FNTB | P49356 | 6/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | PDE4A | P27815 | 4/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.41 |
| ▸ | BAZ2B | Q9UIF8 | 3/20 | 0.38 |
| ▸ | BAZ2A | Q9UIF9 | 3/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7373238 | 0.78 | MAPT (0.42) | FNTAFNTBKDM4EALDH1A1GLA | |
| SCHEMBL7437082 | 0.78 | GAA (0.44) | FNTAFNTBKDM4EALDH1A1GLA | |
| SCHEMBL9531120 | 0.78 | FNTA (0.59) | FNTAFNTBKDM4EALDH1A1GLA | |
| SCHEMBL9531095 | 0.75 | FNTA (0.69) | FNTAFNTBMAPTTP53BAZ2B | |
| SCHEMBL18549567 | 0.75 | TP53 (0.44) | FNTAFNTBKDM4EALDH1A1GLA | |
| SCHEMBL6369605 | 0.75 | KCNH2 (0.56) | FNTAFNTBKDM4EALDH1A1GLA | |
| SCHEMBL10797200 | 0.75 | FNTA (0.59) | FNTAFNTBKDM4EALDH1A1GLA | |
| SCHEMBL9531986 | 0.75 | FNTA (0.60) | FNTAFNTBKDM4EALDH1A1GLA | |
| SCHEMBL27767830 | 0.75 | FNTA (0.60) | FNTAFNTBKDM4EALDH1A1GLA | |
| SCHEMBL27843160 | 0.73 | FNTA (0.58) | FNTAFNTBKDM4EALDH1A1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101309922-A | Amino-aza-adamantane derivatives and methods of use | ABBOTT LAB (US) | 2008-11-19 | — | — | CN | claimed |
| US-20080234308-A2 | Amino-Aza-Adamantane Derivatives and Methods of Use | ABBOTT LABORATORIES (US) | 2008-09-25 | — | — | US | claimed |
| US-20070072892-A1 | Amino-aza-adamantane derivatives and methods of use | ABBOTT LABORATORIES | 2007-03-29 | — | — | US | claimed |
| US-8586746-B2 | Amino-aza-adamantane derivatives and methods of use | ABBVIE INC. (US) | 2013-11-19 | — | — | US | disclosed |
| CN-102816165-A | Amino-aza-adamantane derivatives and methods of use | ABBOTT LAB | 2012-12-12 | — | — | CN | disclosed |
| EP-2476681-A2 | Amino-aza-adamantane derivatives and methods of use | Abbott Laboratories (US) | 2012-07-18 | — | — | EP | disclosed |
| CN-101309922-A | Amino-aza-adamantane derivatives and methods of use | ABBOTT LAB (US) | 2008-11-19 | — | — | CN | disclosed |
| US-20080234308-A2 | Amino-Aza-Adamantane Derivatives and Methods of Use | ABBOTT LABORATORIES (US) | 2008-09-25 | — | — | US | disclosed |
| EP-1926731-A2 | AMINO-AZA-ADAMANTANE DERIVATIVES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2008-06-04 | — | — | EP | disclosed |
| WO-2007038058-A2 | AMINO-AZA-ADAMANTANE DERIVATIVES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2007-04-05 | — | — | WO | disclosed |
| US-20070072892-A1 | Amino-aza-adamantane derivatives and methods of use | ABBOTT LABORATORIES | 2007-03-29 | — | — | US | disclosed |
| EP-0289170-B1 | AZABICYCLIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | BEECHAM GROUP PLC (GB) | 1993-06-23 | — | — | EP | disclosed |
| US-5219850-A | Anyiolytic agents, gastrointestinal disorders, antiserotonin agents | G. D. SEARLE & CO. (US) | 1993-06-15 | — | — | US | disclosed |
| US-5196547-A | Meso-azacyclic amides of imidazopyridine carboxylic acids and analogs thereof | G. D. SEARLE & CO. (US) | 1993-03-23 | — | — | US | disclosed |
| EP-0530353-A1 | NEW IMIDAZOPYRIDINES AS SEROTONERGIC 5-HT 3? ANTAGONISTS | G.D. SEARLE & CO. (US) | 1993-03-10 | — | — | EP | disclosed |
| EP-0504679-A1 | New imidazopyridines as serotonergic 5-HT3 antagonists | G.D. Searle & Co. (US) | 1992-09-23 | — | — | EP | disclosed |
| WO-1992015593-A1 | NEW IMIDAZOPYRIDINES AS SEROTONERGIC 5-HT3 ANTAGONISTS | G.D. SEARLE & CO. (US) | 1992-09-17 | — | — | WO | disclosed |
| US-5137893-A | Anxilytic agents; antidepressants; antiemetics | G. D. SEARLE & CO. (US) | 1992-08-11 | — | — | US | disclosed |
| US-4882327-A | NERVOUS SYSTEM DISORDERS | BEECHAM GROUP P.L.C. (GB) | 1989-11-21 | — | — | US | disclosed |
| EP-0289170-A2 | Azabicyclic compounds, process for their preparation and pharmaceutical compositions containing them | BEECHAM GROUP PLC (GB) | 1988-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072892-A1 | Amino-aza-adamantane derivatives and methods of use | CHRNA7, CHRNA5, CHRNA1 | FNTA 2065/4885FNTB 2782/4885KDM4E 1441/4885 |
| US-20080234308-A2 | Amino-Aza-Adamantane Derivatives and Methods of Use | CHRNA7, CHRNA5, CHRNA1 | FNTA 2065/4885FNTB 2782/4885KDM4E 1441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.